Next steps unclear as Roche's inclacumab meets Phase II endpoint in post-angioplasty study

Roche's inclacumab (RG1512) reduced heart tissue damage in patients with acute coronary syndromes who were dosed with the p-selectin antagonist prior to angioplasty in a Phase II clinical trial, but the Swiss drug maker has not indicated how or whether it will move forward with the monoclonal antibody licensed from Genmab.